Obesity

David Rometo, MD, weighs various weight loss treatments, their success, and sustainability.

David Rometo, MD, of UPMC, addresses stigma surrounding obesity and group setting weight loss intervention therapies and how consults benefit patients.

Research highlights disparities in anti-obesity medication use and metabolic and bariatric surgery.

The European Association for the Study of Obesity now recommends the 2 treatments for obesity and most associated complications.

Here are 5 reasons why bariatric surgery may be better for weight loss than GLP-1 receptor agonists

Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.

Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.

Bariatric surgery is more efficient at increasing weight loss and more cost-effective than GLP-1 RAs.

Elena Losina, PhD, codirector of the Orthopedics and Arthritis Center for Outcomes Research at Brigham and Women’s Hospital, discusses the cost-effectiveness of varying weight loss interventions.

Researchers in Denmark observed a significant drop-off in anti-obesity drug usage after 1 year in first-time users.

This commentary calls for health care systems to deliver equitable care for people living with obesity by addressing weight bias and updating standards in obesity care.

Bariatric surgery reduces the likelihood of obesity-related comorbidities compared with nonsurgical weight loss interventions.

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.

Researchers call for further studies on GLP-1 initiation after bariatric surgery to better understand its real-world impact.

Male and female fat deposit distribution was associated with an increased cardiovascular age-delta; however, some adiposity phenotypes seen as beneficial in one sex were a risk in the other.

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

Rising prescription drug costs challenge US health care, prompting calls for reform and innovative solutions to enhance affordability and access for patients.

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and data-driven strategies in Philadelphia, Pennsylvania, and Wilmington, Delaware, for sustainable health programs.

A recent study aimed to assess evidence on the safety and complications of preoperative glucagon-like peptide-1 (GLP-1) receptor agonist use.

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

A new model was linked to decreased BMI, caloric intake, and loss of control eating in veterans with binge eating disorders or subjective binge eating episodes.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Prenatal exposure to air pollution was associated with childhood obesity risk in a recent study, highlighting the urgent need for environmental health awareness.

Racial disparities in childhood obesity have risen due to social determinants, food insecurity, and systemic barriers, impacting minority communities across the US.